RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
Glen Rock, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the appointment of Dr. Dariusz Nasiek MD, MBA to its board of directors. Dr. Nasiek is a dedicated anesthesiologist with expertise in anesthesiology and interventional pain management. Dr. Nasiek is board certified by the American Board of Anesthesiology, the American Board of Pain Medicine and the American Board of Interventional Pain Physicians. Dr. Nasiek is also a Life Member of the American Society of Interventional Pain Physicians and a Member of the International Spine Intervention Society. He has been a practicing physician for the last 35 years. Since 2006, he has been the Managing Partner of Allied Neurology & Interventional Pain Practice, and since 2008, he has served as the Director of Anesthesiology at Hackensack Surgery Center. Dr. Nasiek is a leader specializing in non-surgical options for the treatment of spinal and non-spinal pain and is a pioneer in the use of innovative techniques in the cervical, thoracic and lumbar spine. His forward-looking approaches to pain management, regenerative medicine and tissue healing are described in the new 2nd Edition of his book entitled, “PRP, Platelet Rich Plasma: A New Paradigm in Regenerative Medicine.”
Related news for (RSPI)
- RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
- RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
- RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
- RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient